ARUP LABORATORIES | aruplab.com
500 Chipeta Way, Salt Lake City, Utah 84108-1221
phone: 801-583-2787, toll free: 800-522-2787
Tracy I. George, MD, Chief Medical Officer

Patient Report

Patient Age/Sex: Unknown

Specimen Collected: 16-Dec-21 11:24

Neuronal Nuclear Abs IgG, IB, CSF | **Received: 16-Dec-21 11:24** | **Report/Verified: 16-Dec-21 11:27**

Procedure	Result	Units	Reference Interval
Neuronal Nuclear Ab (Hu) IgG,IB,CSF	**Low Positive** * i1		Negative
Neuronal Nuclear Ab (Ri) IgG,IB,CSF	**Positive** * i2		Negative
Neuronal Nuclear Ab (Yo) IgG,IB,CSF	**Positive** * i3		Negative
Neuronal Nuclear Ab (TR/DNER) IgG,CSF	**High Positive** * i4		Negative

Neuronal Nuclear Antibody Titer, IgG CSF | **Received: 16-Dec-21 11:24** | **Report/Verified: 16-Dec-21 11:27**

Procedure	Result	Units	Reference Interval
Neuronal Nuclear Ab Titer,IgG CSF	**1:80** * i5		< 1:1

Paraneoplastic Reflexive Panel, CSF | **Received: 16-Dec-21 11:24** | **Report/Verified: 16-Dec-21 11:27**

Procedure	Result	Units	Reference Interval
Paraneoplastic Abs (PCCA/ANNA) IgG,CSF	**ANNA Detected** * f1 i6		None Detected
CV2.1 Ab IgG Screen, CSF	**Detected** * t1 i7		< 1:1
SOX1 Antibody,IgG by Immunoblot,CSF	**High Positive** * i8		Negative
Amphiphysin Antibody, CSF	**Low Positive** * i9		Negative

CV2.1 Ab IgG Titer, CSF | **Received: 16-Dec-21 11:24** | **Report/Verified: 16-Dec-21 11:27**

Procedure	Result	Units	Reference Interval
CV2.1 Antibody IgG Titer by IFA,CSF	**1:40** * i10		<1.1

Interpretive Text

t1: 16-Dec-21 11:24 (CV2.1 Ab IgG Screen, CSF)
CV2.1 Antibody, IgG is detected. Titer results to follow. Additional charges apply.

Result Footnote

f1: Paraneoplastic Abs (PCCA/ANNA) IgG, CSF

Antibodies detected, therefore IFA titer and Immunoblot testing to be performed.

Test Information

i1: Neuronal Nuclear Ab (Hu) IgG, IB, CSF
INTERPRETIVE INFORMATION: Neuronal Nuclear Ab (Hu) IgG, IB, CSF
This test detects IgG antineuronal antibodies to Hu, Ri, and Yo and Tr (DNER) antigens.

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

Test Information

i1: Neuronal Nuclear Ab (Hu) IgG, IB, CSF

Antineuronal antibodies serve as markers that aid in discriminating between a true paraneoplastic neurological disorder (PND) and other inflammatory disorders of the nervous system. Anti-Hu (antineuronal nuclear antibody, type I) is associated with small cell lung cancer. Anti-Ri (antineuronal nuclear antibody, type II) is associated with neuroblastoma in children and with fallopian tube and breast cancer in adults. Anti-Yo (anti-Purkinje cell cytoplasmic antibody) is associated with ovarian and breast cancer. Anti-Tr(DNER) is associated with Hodgkin's lymphoma.

The presence of one or more of these antineuronal antibodies supports a clinical diagnosis of PND and should lead to a focused search for the underlying neoplasm.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i2: Neuronal Nuclear Ab (Ri) IgG, IB, CSF

INTERPRETIVE INFORMATION: Neuronal Nuclear Ab (Ri) IgG, IB, CSF

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i3: Neuronal Nuclear Ab (Yo) IgG, IB, CSF

INTERPRETIVE INFORMATION: Neuronal Nuclear Ab (Yo) IgG, IB, CSF

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i4: Neuronal Nuclear Ab (TR/DNER) IgG, CSF

INTERPRETIVE INFORMATION: Neuronal Nuclear Ab (TR/DNER) IgG, CSF

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i5: Neuronal Nuclear Ab Titer, IgG CSF

INTERPRETIVE INFORMATION: Neuronal Nuclear Ab Titer, IgG CSF

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Test Information

i6: Paraneoplastic Abs (PCCA/ANNA) IgG, CSF

INTERPRETIVE INFORMATION: Paraneoplastic Abs (PCCA/ANNA) IgG, CSF

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i7: CV2.1 Ab IgG Screen, CSF

INTERPRETIVE INFORMATION: CV2.1 IgG Ab with Reflex to Titer, CSF

CV2.1 antibodies aid in discriminating between chronic paraneoplastic neurological disorder (PND) and other inflammatory disorders of the nervous system. Anti-CV2.1 is associated with small-cell lung cancer and thymoma.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement D: aruplab.com/CS.

i8: SOX1 Antibody, IgG by Immunoblot, CSF

INTERPRETIVE INFORMATION: SOX1 Antibody, IgG by Immunoblot, CSF

SOX1 antibody is detected in patients with Lambert-Eaton myasthenic syndrome (LEMS) and in patients with paraneoplastic cerebellar degeneration (PCD), paraneoplastic and nonparaneoplastic neuropathy. SOX1 antibody is associated with small cell lung cancer. A negative test result does not rule out a diagnosis of LEMS or other causes of paraneoplastic neurological syndrome.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement D: aruplab.com/CS

i9: Amphiphysin Antibody, CSF

INTERPRETIVE INFORMATION: Amphiphysin Antibody IgG, CSF

Amphiphysin antibody is present in about 5 percent of patients with stiff-person syndrome and is found variably in other causes of paraneoplastic neurological syndrome (PNS). Amphiphysin antibody is mainly associated with small-cell lung cancer and breast tumors.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i10: CV2.1 Antibody IgG Titer by IFA, CSF

INTERPRETIVE INFORMATION: CV2.1 Antibody IgG Titer by IFA, CSF

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement D: aruplab.com/CS.

ARUP LABORATORIES | aruplab.com
500 Chipeta Way, Salt Lake City, Utah 84108-1221
phone: 801-583-2787, toll free: 800-522-2787
Tracy I. George, MD, Chief Medical Officer

Patient Age/Sex: Unknown

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab